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Abstract
Background: Tetra-O-methyl nordihydroguaiaretic acid, also known as terameprocol (TMP), is a naturally occurring
phenolic compound found in the resin of the creosote bush. We have shown previously that TMP will suppress
production of certain inflammatory cytokines, chemokines and lipids from macrophages following stimulation with
LPS or infection with H1N1 influenza virus. In this study our goal was to elucidate the mechanism underlying TMP-
mediated suppression of cytokine and chemokine production. We focused our investigations on the response to
LPS and the NF-B protein RelA, a transcription factor whose activity is critical to LPS-responsiveness.
Methods: Reporter assays were performed with HEK293 cells overexpressing either TLR-3, -4, or -8 and a plasmid
containing the luciferase gene under control of an NF-B response element. Cells were then treated with LPS, poly
(I:C), or resiquimod, and/or TMP, and lysates measured for luciferase activity.
RAW 264.7 cells treated with LPS and/or TMP were used in ChIP and EMSA assays. For ChIP assays, chromatin was
prepared and complexes precipitated with anti-NF-B RelA Ab. Cross-links were reversed, DNA purified, and
sequence abundance determined by Q-PCR. For EMSA assays, nuclear extracts were incubated with radiolabeled
probes, analyzed by non-denaturing PAGE and visualized by autoradiography.
RAW 264.7 cells treated with LPS and/or TMP were also used in fluorescence microscopy and western blot experi-
ments. Translocation experiments were performed using a primary Ab to NF-B RelA and a fluorescein-conjugated
secondary Ab. Western blots were performed using Abs to IB-a and phospho-IB-a. Bands were visualized by
chemiluminescence.
Results: In reporter assays with TLR-3, -4, and -8 over-expressing cells, TMP caused strong inhibition of NF-B-
dependent transcription.
ChIP assays showed TMP caused virtually complete inhibition of RelA binding in vivo to promoters for the genes
for TNF-a, MCP-1/CCL2, and RANTES/CCL5 although the LPS-dependent synthesis of IB-a was not inhibited. EMSA
assays did not reveal an effect of TMP on the binding of RelA to naked DNA templates in vitro.
TMP did not inhibit the nuclear translocation of NF-B RelA nor the phosphorylation of IB-a.
Conclusion: TMP acts indirectly as an inhibitor of NF-B-dependent transcription by preventing RelA from binding
the promoters of certain key cytokine and chemokine genes.
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The NF-B proteins are sequence-specific transcription
factors that play critical roles in the immune system.
NF-B proteins regulate the expression of cytokines, che-
mokines, growth factors, and inflammatory enzymes in
response to activation of T-cell, B-cell, Toll/IL-1R, and
TNF-a receptors [1,2]. The NF-B family of proteins is
characterized by the presence of a conserved 300 amino
acid Rel Homology Domain (RHD) which controls
dimerization, DNA binding, and association with the
inhibitory IB proteins [3]. The five members of the
mammalian NF-B family; RelA (p65), RelB, c-Rel, NF-
B1 (p50) and NF-B2 (p52) are present in unstimulated
cells as homo- or heterodimers bound to inhibitory IB
proteins. This association prevents NF-B proteins from
translocating to the nucleus, thereby maintaining an
inactive state [4]. In response to inflammatory stimuli
such as TNF-a, IL-1, or LPS, multiple signaling pathways
are activated resulting in the phosphorylation of IB-a
[5,6]. Subsequent poly-ubiquitination and proteosomal
degradation of IB-a permits the translocation of NF-B
proteins into the nucleus where transcription is activated
[7,8]. NF-B dimers exhibit variable binding affinities for
consensus B binding sites. These proteins also differ in
their ability to initiate transcription; RelA, RelB and c-Rel
have been shown to have potent trans-activating
domains, while NF-B proteins that lack transactivating
domains such as p50 and p52 have been to shown to
mediate transcriptional repression [3]. Activated NF-B
proteins can be inhibited by newly synthesized IBp r o -
teins which cause re-export back to the cytosol [9].
Extracts of the Creosote bush, Larrea tridentata, found
in deserts of the Southwestern United States and Northern
Mexico, have been used for centuries by indigenous peo-
ples to treat inflammatory disorders. Many of the medic-
inal effects of L. tridentata have been ascribed to the
polyphenolic compound nordihydroguaiaretic acid
(NDGA) [10]. In addition, L. tridentata also contains poly-
phenolic compounds with modifications to the backbone
structure of NDGA [11]. A number of these compounds
have been examined for their antiviral activity. For exam-
ple, an analysis of eight methylated forms of NDGA for
their ability to inhibit HIV replication revealed that tetra-
O-methyl NDGA, also known as terameprocol (TMP), dis-
played the highest level of activity. Mechanistic studies
suggest that TMP mediates this effect by inhibiting HIV
Tat-mediated transactivation [12]. TMP has also been
shown to block the replication of herpes simplex virus
in vitro and this effect has been attributed to the drug’s
ability to block the binding of the transcription factor Sp1
to viral DNA, which is required for virus replication [13].
Based on these reports, we have recently evaluated the
efficacy of TMP as an anti-inflammatory agent. We
reasoned that since inflammation is heavily dependent on
de novo transcription, TMP might be a useful therapeutic
compound. We found that TMP exerted a range of effects
on various inflammatory cytokines, chemokines and lipid
mediators both in vivo and in vitro following treatment
with LPS or infection with H1N1 influenza A virus strain
PR/8/34 [14]. TMP strongly inhibited the production
of TNF-a, MCP-1/CCL2, G-CSF, and several prostaglan-
dins, while modestly inhibiting the production of IL-6 and
MIP-1a/CCL3. Since the NF-BR e l Ap r o t e i nh a sb e e n
reported to regulate the expression of several of these
genes [15-18]; we have focused our current studies on
how TMP modulates RelA activation and occupancy at its
cognate DNA binding motifs. We report that TMP did
not affect the cytoplasmic activation and nuclear localiza-
tion of RelA in RAW 264.7 cells following treatment with
LPS. However, reporter assays revealed strong inhibition
of NF-B-dependent transcription. Chromatin immuno-
precipitation (ChIP) assays revealed that TMP abrogated
the LPS-induced binding of RelA at the TNF-a,M C P - 1 /
CCL2, and RANTES/CCL5 promoters despite its inability
to block NF-B association with electrophoretic mobility
shift assay (EMSA) probes in vitro. We conclude, there-
fore, that TMP acts indirectly to inhibit the binding of
RelA to the promoters of certain key pro-inflammatory
cytokine and chemokine genes. Taken together our data
suggest that TMP could be useful for the treatment of
inflammatory disorders where NF-BR e l A - d e p e n d e n t
transcription plays a pathogenic role.
Methods
Cells and media
RAW 264.7 cells were obtained from the American
Type Culture Collection (Manassas, VA) and were cul-
tured in Dulbecco’s modification of minimal essential
medium (DMEM) with 4 mM L-glutamine, 4.5 g/L glu-
cose, and 1.5 g/L sodium bicarbonate with 10% FCS.
Media and supplements were obtained from Sigma-
Aldrich, St. Louis, MO and Cellgro, Manassas, VA. FCS
was obtained from Atlanta Biologicals, Atlanta, GA and
Cellgro. Constitutive TLR3(293/TLR3-YFP), TLR8(293/
TLR8) (InvivoGen, San Diego, CA) and TLR4(293/
TLR4-YFP/MD2) (a gift from D. Golenbock) expressing
HEK293 cells were grown in DMEM supplemented with
10% FCS, 1% antibiotics, 20 μg/ml gentamicin at 37°C.
Stable expression of TLRs was maintained with the
addition of 10 μg/ml blasticidin for (293/TLR3) and
(293/TLR8) cells, and 400 μg/ml of G418 (Geneticin)
for (293/TLR4) cells.
Chemicals and biological reagents
Unless otherwise indicated, reagents were purchased
from Sigma-Aldrich. TMP was supplied by Erimos
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solvent for TMP in all experiments. The maximum
DMSO concentration was 0.1% in all assays. This con-
centration of DMSO was tested in all assays and did not
affect the results. LPS from Salmonella Minnesota R595
was purchased from LIST Biological Laboratories, Inc.
(Campbell, CA).
Quantitative RT-PCR analysis
Total RNA was extracted using the RNAeasy kit (Qiagen,
Valencia, CA) according to the manufacturer’s specifica-
tions. Residual genomic DNA was eliminated using on-
column DNase digestion with the RNase-free DNase set
(Qiagen) and resulting extracts were resuspended in nucle-
ase free water. Amount and purity of RNA was determined
using a Nanodrop 1000 spectrophotometer (ThermoFisher
Scientific, Waltham, MA). RNA (1 μg) was denatured and
reverse transcription was performed with the Improm ll
reverse transcription kit (Promega, Madison, WI) in a reac-
tion mix containing random hexamers as primers (50 ng/
μl) for 60 min at 42°C. The iQTM SYBR Green supermix
kit (BioRad, Hercules, CA), was used for Real-time PCR
analysis. cDNA was amplified using primers specific for
murine GAPDH, TNF-a, MCP-1/CCL2, and RANTES/
CCL5 genes. Primer combinations are GAPDH [antisense:
5’ ATG TCA GAT CCA CAA CGG ATA GAT 3’; sense:
5’ ACT CCC TCA AGA TTG TCA GCA AT 3’]; TNF-a
[antisense: 5’ AGA AGA GGC ACT CCC CCA AAA 3’;
sense: 5’ CCG AAG TTC AGT AGA CAG AAG AGC G
3’]; MCP-1/CCL2 [sense: 5’ CAC TAT GCA GGT CTC
TGT CAC G 3’; antisense: 5’ GAT CTC ACT TGG TTC
TGG TCC A 3’]; RANTES/CCL5: [sense: 5’ CCC CAT
ATG GCT CGG ACA CCA 3’;a n t i s e n s e :5 ’ CTA GCT
CAT CTC CAA ATA GTT GAT 3’]. All primer pairs were
purchased from Integrated DNA Technologies (Coralville,
IA). PCR was performed in 96 well plates (Eppendorf AG,
Hamburg, Germany). Samples were amplified for a total of
50 cycles, followed by a meltcurve analysis to ensure the
specificity of reactions. To generate a standard curve, total
RNA was isolated from the cells and 300-600 bp fragments
of the gene of interest were amplified by RT-PCR using
cognate primer sets. PCR fragments were gel purified,
quantified, and the copy number was calculated. Serial ten-
fold dilutions were prepared for use as templates to gener-
ate standard curves. All samples were normalized to
amplified murine GAPDH. GAPDH control was analyzed
per plate of experimental gene to avoid plate-to-plate varia-
tion. Final RT-PCR data is expressed as the ratio of copy
numbers of experimental gene per 10
3 or 10
4 copies of
GAPDH for samples performed in duplicates.
Western blot analysis
After treatments, cell monolayers were washed twice
with cold phosphate buffered saline (PBS), solubilized in
lysis buffer (50 mM Hepes, pH 7.4, 1 mM EGTA, 1 mM
EDTA, 0.2 mM sodium orthovanadate, 1 mM phenyl-
methylsulfonyl fluoride, 0.2 mM leupeptin, 0.5% SDS)
and collected by scraping. The protein concentration for
each sample lysate was determined using the Pierce
BCA system (Pierce, Rockford, IL). Equal protein sam-
ples (25 μg) were loaded on 12% Tris-Glycine gels and
subjected to electrophoresis using the Novex Mini-Cell
System (Invitrogen). Following transfer, and blocking,
blots were probed with antibodies specific for the phos-
phorylated serine 32 residue of IB-a and total IB-a
protein (Cell Signaling; Beverly, MA). Bands were visua-
lized using the SuperSignal Chemiluminescent system
(Pierce).
Immunofluorescence
RAW 264.7 cells were seeded onto 8 well chamber slides
and stimulated with 1 μg/ml of LPS or co-stimulated
with 1 μg/ml of LPS and 25 μMT M Pf o rv a r i o u s
amounts of time. To visualize NF-B subcellular localiza-
tion at the end of each treatment period, cells were
briefly washed with phosphate-buffered saline, fixed in
4% paraformaldehyde, permeabilized with 0.1% Triton X-
100, and blocked (2% bovine serum albumin, 5% normal
horse serum, and 10 mM glycine in phosphate-buffered
saline). The cells were then incubated with a rabbit
monoclonal anti-NF-B (p65) antibody (Santa Cruz Bio-
technologies, Santa Cruz, CA), followed by incubation
with a goat anti-rabbit fluorescein isothiocyanate-conju-
gated secondary antibody (Southernbiotech, Birmingham,
AL). Fluorescence was viewed using a Zeiss Axioskop 2
microscope (Zeiss AG, Oberkochen, DE). Images were
captured using a spot camera (Diagnostic Instruments,
Inc., Sterling Heights, MI).
Cytokine Measurements
MCP-1/CCL2 and TNF-a ELISA kits were purchased
from R&D Systems (Minneapolis, MN), Assay Designs
(Ann Arbor, MI) or eBioscience (San Diego, CA). RAW
264.7 cells were stimulated with 1 μg/ml of LPS for 24
hrs and supernatants were collected for ELISA assays. In
each case, sample values were interpolated from stan-
dard curves. Optical density was determined using a
PolarStar microplate reader (BMG Labtechnologies,
Durham, NC).
Reporter Assays
Reporter assays were performed using a luciferase gene
under the control of an NF-B response element (NF-B
-Luc; Stratagene, Santa Clara, CA). Briefly, the plasmid
contains 5 consecutive NF-B binding motifs designed
from a consensus sequence cloned into a PGL3 vector.
100 ng each of NF-B-Luc and pCMV beta (b-Gal)
(Clontech) and 300 ng of pcDNA6 (Invitrogen) were
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293/TLR8 cells using the TransIT-LT1 transfection
reagent (Mirus, Madison, WI). pcDNA6 was used to
keep the overall DNA concentration at a total of 500 ng
which has proven itself suitable for reporter assay in this
system. At 24 h post-transfection, cells were either
treated for 4 hours with 20 μg/ml poly(I:C) (pIC; Calbio-
c h e m ,G i b b s t o w n ,N J ) ,1μg/ml LPS or 1 μg/ml resiqui-
mod (R-848; Axxora, San Diego, CA) alone, or co-treated
with 25 μM TMP. Following treatment, cells were lysed
in reporter lysis buffer (Promega, Madison, WI) contain-
ing 0.1% Triton X-100 and assayed for Luc and b-Gal
activities using a Promega Luc assay system and an
ONPG (o-nitrophenyl-b-D-galactopyranoside)-based b-
Gal assay. b-Gal activity was used to normalize the Luc
data for all experiments. All data are expressed as relative
light units/mU of b-Gal activity.
Chromatin immunoprecipitation (ChIP) assays
4.5 × 10
7 RAW 264.7 cells were stimulated with 1 μg/ml
LPS or co-treated with 1 μg/ml LPS and 25 μMT M P
for 4 hours and chromatin was isolated by methods pre-
viously described [19]. Briefly, after treatments, cells
were harvested and nucleoprotein complexes were
crosslinked with formaldehyde (1% final) with shaking
for 10 min at room temperature, followed by incubation
with glycine (125 mM final) for an additional 5 min.
Cells were pelleted, washed and resuspended in 500 μl
lysis buffer (10 mM Tris-HCl, pH7.5, 10 mM NaCl, 3
mM MgCl2, and 0.5% NP-40) supplemented with 1 mM
PMSF and 1× Protease Inhibitor Cocktail (PIC, Roche).
Nuclei were pelleted and resuspended in Micrococcal
nuclease buffer (10 mM Tris-HCl, pH 7.5, 10 mM NaCl,
3m MM g C l 2, 1 mM CaCl2,4 %N P - 4 0 )s u p p l e m e n t e d
with 1 mM PMSF and 1× PIC, and chromatin was
sheared with the addition of 10 U MNase for 7 min at
37°C. Digestion was stopped with the addition of EDTA
(10 mM final), and the resultant chromatin was stored
at -80°C. Shearing was confirmed by electrophoresis and
>80% of the DNA was in fragments <400 bp.
Using magnetic capture, Protein A and G-coupled
Dynabeads (Invitrogen) (5 μl each/IP) were washed 2×
(100 μl/IP) in RIPA buffer (10 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton
X-100, 0.1% SDS, 0.1% NaDeoxycholate and sheared sal-
mon sperm DNA (0.5 mg/ml). Beads were conjugated
with 1-5 μg antibody for 1 h at 4°C in RIPA buffer sup-
plemented with 1 mM PMSF and 1× PIC. Conjugated
antibody:bead complexes were washed 3× in RIPA buf-
fer as described above, and protein-DNA complexes
were immunoprecipitated for 2 h at 4°C with rotation in
RIPA buffer (100 μl) supplemented with 1 mM PMSF,
1× PIC and chromatin (10
5 cell equivalents). Following
IP, beads were successively washed 4× in RIPA buffer
and 2× in TE 8.0, and protein-DNA complexes were
eluted in 100 mM NaHCO3 by gentle vortexing for 15
min at room temp. Supernatants were recovered and
crosslinks were reversed in NaCl (100 mM final)
together with matched input samples by heating at 95°C
for 15 min. Proteins were removed using Proteinase K
(10 μg/ml final) for 1 h at 45°C and DNA was purified
using Qiaquick nucleotide removal columns (Qiagen)
according to the manufacturer’s instructions.
ChIP Q-PCR and data analysis
For realtime PCR, bound (3 μl) and input samples were
amplified in a MyIQ thermal cycler (Bio-RAD) using 1×
SensiMix Plus (Quantace, London, UK) and primers spe-
c i f i cf o rt h eR e l Ab i n d i n gs i t e sa tt h eT N F - a,M C P - 1 /
CCL2 and RANTES/CCL5 promoters. TNF-a:( f o r -
ward:5’-TCTCAAGCTGCTCTGCCTTC-3’; reverse:5’-
CACCAGGATTCTGTGGCAAT-3’). RANTES/CCL5:
(Forward:5’-TGGAGGGCAGTTAGAGGCAGAG-3’;
reverse:5’-AGCCAGGGTAGCAGAGGAAGTG-3’)a n d
MCP-1/CCL2:(Forward:5’-ATTCTTCCCTCTTTCCC
CCCCC-3’;reverse:5’-TCCGCTGAGTAAGTGCAGA
GCC-3’) Cycling parameters for 20 μl reactions were
95°C 10 min, followed by 50 cycles of 95°C, 20 s; 60°C, 30
s; 72°C, 30 s, for all genes listed. Fold enrichment in the
bound fractions relative to input was calculated as pre-
viously described [20], and the average enrichment for
triplicate amplifications was reported.
Electrophoretic mobility shift assays (EMSA)
RAW 264.7 nuclear extracts and radioactive probes were
prepared and EMSA reactions performed as previously
described [21]. Sequences of wildtype and mutant oligo-
nucleotide EMSA probes include: wildtype TNF-a B3
sense (5’-AACAGGGGGCTTTCC-3’) and antisense (5’-
AGGAGGGAAAGCCCC-3’), and mutant TNF-a B3
sense (5’-AACAGGGGGCTGAGCCTC-3’)a n da n t i -
sense (5’-GAGGCTCAGCCCCCTGTT-3’).
Statistical Analysis
All graphs and statistical analyses were produced using
Prism software (GraphPad Software Inc., La Jolla CA).
Results
TMP acts early to inhibit synthesis of TNF-a and
MCP-1/CCL2 mRNAs
We have previously shown that TMP inhibits the LPS-
induced production of TNF-a and MCP-1/CCL2 from
RAW 264.7 macrophage-like cells [14]. Representative
experiments illustrating this effect are shown in Figures
1A and 1B. Typically, following a 24 h treatment with 1
μg/ml LPS in the presence of 25 μM TMP, levels of
TNF-a and MCP-1/CCL2 are suppressed by 40 and
80%, respectively. Previously we found that the TMP-
mediated reduction in these protein levels correlated
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leading us to speculate that TMP could interfere with
transcription [14]. However, because regulation of cyto-
kine and chemokine mRNA can be complex, we sought
direct evidence for an early effect of TMP on mRNA
synthesis. As shown in Figure 1C, the effect of TMP on
the synthesis of TNF-a mRNA was evident early and
maintained throughout the 8 h experiment [14] consis-
tent with an effect on the transcriptional activation of
the TNF-a gene. The rapid rise and fall in levels of
TNF-a mRNA following treatment with LPS is typical
and has been attributed to the action of various tran-
scription factors [21,22] followed by tristetrapolin
(TTP)-mediated mRNA degradation [23,24]. As shown
in Figure 1D, an early effect of TMP on the synthesis of
MCP-1/CCL2 mRNA was also noted; results that are
again consistent with an effect of TMP on transcrip-
tional activation. In this case, however, we also observed
a reduction in steady state levels of MCP-1/CCL2
mRNA in the presence of TMP (Figure 1D). This effect
was selective for MCP-1/CCL2 mRNA; TMP did not
alter TNF-a mRNA expression kinetics.
TMP inhibits NF-B dependent reporter activity
NF-B proteins, primarily RelA/NF-B1 heterodimers,
have been reported to play a key role in the transcriptional
activation of cytokine genes after LPS stimulation [25].
Therefore, we hypothesized, that the inhibitory effects of
TMP on the transcription of TNF-a and MCP-1/CCL2
mRNAs might stem from the effect of the drug on the
activity of NF-B proteins. To test this hypothesis, we per-
formed reporter assays with cells expressing an NF-B
response element. HEK293 cells co-expressing TLR4 and
MD2 (a co-receptor needed for TLR4 signaling) (HEK293/
TLR4-YFP/MD2) were stimulated with 1 μg/ml of LPS or
1 μg/ml of LPS and 25 μM of TMP for a period of 4 hours
and cell lysates were analyzed for NF-B dependent luci-
ferase activity. As shown in Figure 2A, LPS stimulation
strongly increased NF-B dependent reporter activity
approximately 7 fold. This effect was inhibited by TMP by
approximately 60%, a result consistent with the hypothesis
that TMP inhibits the activity of NF-B. This effect was
dose dependent with a concentration of 12.5 μMT M P
inhibiting NF-B reporter activity by 35% (data not
shown). It should also be noted that western blots with a
TLR-4 specific Ab did not reveal an effect of TMP on the
expression of TLR-4 following transfection (data not
shown).
The possibility that TMP was affecting the activity of
LPS and/or its receptor, as opposed to NF-B-dependent
transcription, was examined by testing the effects of TMP
on TLR-3 and TLR-8-mediated activation of NF-B
[26,27]. The natural ligands for TLR-3 and TLR-8 are dou-
ble and single stranded RNA, respectively. In these experi-
ments we used the artificial ligands poly(I:C) for TLR-3
and resiquimod (R-848) for TLR-8. HEK293/TLR3 and
HEK293/TLR8 cells were stimulated with either 20 μg/ml
poly(I:C) or 1 μg/ml R-848, respectively. As with LPS, we
found that TMP blocked both poly(I:C)- and R-848-
induced, NF-B-dependent reporter activity (Figures 2B
and 2C, respectively). Taken together these data suggest
that TMP mediates a broad, receptor-independent, inhibi-
tory effect on NF-B-dependent transcription.
TMP inhibits RelA binding to its cognate motifs in vivo
ChIP assays were used next to confirm this hypothesis
and to gain insight into the mechanism of NF-B inhibi-
tion. Furthermore, with these assays we could examine
RelA activity specifically since this is the major NF-B
protein responsible for cytokine and chemokine tran-
scription following LPS stimulation [5]. RAW 264.7 cells
were treated with LPS and/or TMP, the resulting
nucleo-protein complexes were cross-linked, and RelA
specific antibodies were used to precipitate RelA:DNA
complexes. DNA was subsequently purified and ana-
lyzed by quantitative RT-PCR using primers specific for
the NF-Bb i n d i n gs i t e so nt h eT N F - a, MCP-1/CCL2,
and RANTES/CCL5 promoters. RANTES/CCL5 was
included since it’s promoter does contain NF-Bb i n d -
ing sites, although previous studies showed that its
expression was not blocked by TMP. As shown in
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Figure 1 TMP inhibits TNF-a and MCP-1/CCL-2 protein and
mRNA. RAW 264.7 cells were either stimulated with 1 μg/ml of LPS
or 1 μg/ml of LPS and 25 μM TMP. Following 24 h of treatment,
supernatants were collected and levels of TNF-a (A) and MCP-1/
CCL2 (B) were determined by ELISA. To assess the effects of TMP on
the transcription of TNF-a (C) and MCP-1/CCL2 (D) genes, RNA was
prepared from RAW 264.7 cells stimulated with 1 μg/ml of LPS or 1
μg/ml of LPS and 25 μM TMP for the indicated time periods.
Quantitative RT-PCR was used to analyze the levels of TNF-a and
MCP-1/CCL2 mRNA. Asterisks indicate significant differences
between treatments with LPS and LPS and TMP (p < 0.05, T-test).
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binding of RelA to each promoter, an effect that was
completely blocked by treatment with TMP. We con-
clude, therefore, that TMP prevents NF-B-dependent
transcription by preventing RelA from binding to its
cognate motifs on the DNA in vivo.
TMP does not directly inhibit RelA:DNA binding
Loss of RelA binding at the TNF-a promoter in our ChIP
analyses suggests that TMP either directly inhibits RelA:
DNA binding or acts indirectly to alter assembly of the
TNF-a promoter nucleoprotein complex. To determine if
TMP competitively impairs RelA:DNA binding, we tested
the ability of NF-B nuclear proteins to bind radiolabeled
ds oligonucleotides of cognate B sites on the TNF-a pro-
moter by EMSA (Figure 4). LPS treatment of RAW 264.7
cells induced high levels of nuclear protein binding to a
radiolabeled probe of the B3 site (-311 relative to the
TNF-a transcription start site) (Figure 4A, compare lanes
1 and 2). Binding was readily competed by unlabeled wild-
type B3 probe (Figure 4A, lane 3), whereas a 3-base sub-
stitution in the probe abolished competition (lane 4). The
ability of anti-p65 antibody to specifically supershift the
upper nucleoprotein complex (lane 5) confirms the iden-
tity of this band and recapitulates recent findings in LPS-
treated RAW 264.7 cells [28]. In contrast to our in vivo
ChIP analyses, addition of 25 μM TMP during LPS induc-
tion of RAW 264.7 cultures had no apparent impact on
NF-B binding at either the B3 (Figure 4B, lane 3) or
B2 sites of TNF-a (data not shown). Likewise, NFB
binding was unaffected when nuclear extracts from LPS-
treated RAW 264.7 cells were pre-incubated with varying
concentrations of TMP prior to addition of the radiola-
beled DNA probe (Figure 4B, lanes 4-6), suggesting that
TMP does not directly inhibit NFB binding to DNA.
TMP does not inhibit the nuclear translocation of NF-B
RelA
Antibody to RelA was used in immunofluorescence
experiments to determine whether TMP blocked the
nuclear translocation of RelA. As shown in Figures 5A-
C, LPS treatment of RAW 264.7 cells caused strong
nuclear translocation of RelA; twenty min. after treat-
ment with LPS was initiated virtually all cells displayed
nuclear RelA (Figure 5B). At later time points nuclear
staining became more diffuse but overall staining inten-
sity in the nuclear region of the cells remained relatively
constant (Figure 5C and 5G). As shown in Figures 5D-
G, TMP did not affect this process. Nuclear staining
was evident in virtually all cells 20 min. after treatment
with LPS was initiated and signals remained high at sub-
sequent time points. TMP also failed to affect the trans-
location of RelA in C3HA mouse fibroblasts and
NTERA-2 neuronal cells following treatment with LPS
(data not shown). Together, these results suggest that
TMP does not interfere with signaling to, and move-
ment of RelA into the nucleus following treatment with
LPS.
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Figure 2 TMP represses NF-B dependent reporter activity. The
effect of TMP on LPS induced TLR4 signaling was evaluated by
reporter analysis. HEK293/TLR4-YFP/MD2 cells were co-transfected
with NF-B -Luc and b-gal control plasmids then, after 4 hours of
treatment, luciferase activity was measured in cell lysates (A). To
analyze the effects of TMP on other TLR family members HEK293/
TLR3 (B) and HEK293/TLR8 (C) cells were co-transfected as above,
treated for four hours with 10 μg/ml poly(IC) (B) or 1 μg/ml R-848
(C) and/or 25 μM TMP, and luciferase activity determined in cell
lysates. Each experiment was performed at least 3 times and
representative experiments are shown. Asterisks indicate significant
differences between ligand treatments and ligand treatments with
TMP (p < 0.05, T-test).
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Page 6 of 11TMP does not affect the phosphorylation of IB-a
Finally, to confirm this hypothesis we examined the
effects of TMP on the LPS-induced phosphorylation of
IB-a, the final step in the signaling cascade, which
results in dissociation of the RelA/p50 heterodimer from
IB-a, permitting nuclear translocation of RelA/p50 [29].
As shown in Figure 6A, we found that LPS stimulation
induced phosphorylation of IB-a within 10 mins and
that levels of phospho-IB-a remained relatively constant
for up to 4 hours. Note that levels of total IB-a drop
below levels of detection at the 10 min. time point
(Figure 6A). According to the antibody manufacturer,
this occurs because phosphorylation of IB-a is complete
and this modification blocks the binding of the total
IB-a antibody. Detection of total IB-a at later time
points represents newly synthesized, non-phosphorylated
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Figure 3 TMP inhibits RelA DNA binding. RAW 264.7 cells were
either stimulated with 1 μg/ml of LPS or 1 μg/ml of LPS and 25 μM
TMP for 4 hours. Following treatment, protein:DNA complexes were
cross-linked, and RelA binding at the TNF-a (A), MCP-1/CCL2 (B) and
RANTES/CCL5 (C) promoters was assessed by chromatin
immunoprecipitation. Enrichment was calculated relative to pre-IP
input control levels and was normalized to signals obtained with
non-specific IgG control antibodies. Data shown are representative
of two independent experiments and chromatin preparations.
Asterisks indicate significant differences between LPS treatments
and LPS treatments with TMP (p < 0.05, T-test).
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Figure 4 TMP does not impair NFBb i n d i n gin vitro to the
TNF-a promoter. (A) Nuclear extracts from untreated (lane 1) RAW
264.7 cells or cells stimulated 4 hrs with 1 μg/ml LPS (lanes 2-6)
were incubated with a radiolabeled ds oligonucleotide probe to the
B3 site of the TNF-a promoter. Probes were incubated with
nuclear extract alone (lanes 1 and 2), in the presence of 100-fold
molar excess of unlabeled wt (lane 3) or mutant B3 competitor
oligonucleotides (lane 4), or in the presence of the indicated Abs
(lanes 5 and 6). Specific nucleoprotein (filled arrows) and Ab-
supershifted complexes (empty arrows) are indicated. (B) The impact
of TMP on protein binding to TNF-a B3 (upper panels) or control
NF-Y (bottom panel) was assessed in nuclear extracts from LPS-
treated RAW 264.7 cells co-stimulated with TMP (lane 3) or upon
addition of exogenous TMP to the binding reaction (lanes 4-6, 0.25
μM, 2.5 μM, and 25 μM, respectively).
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Page 7 of 11molecules. As shown in Figure 6B, the pattern of IB-a
phosphorylation did not change in the presence of TMP.
Small changes were noted from experiment to experi-
ment however none of these effects were significant
( F i g u r e6 C ) .W ec o n c l u d e ,therefore, that TMP is not
interfering with signaling pathways that result in the acti-
vation and translocation of NF-B. It should also be
noted that TMP did not affect the resynthesis of total
IB-a, which is dependent on RelA ([30]), indicating that
TMP does not inhibit the RelA dependent transcription
of IB-a.
Discussion
Previously we showed that TMP could inhibit the
expression of a number of cytokines and chemokines
following stimulation with LPS [14]. The production of
TNF-a, MCP-1/CCL2, and G-CSF were most strongly
inhibited and we hypothesized that these effects might
stem from effects on NF-B RelA, which is thought to
play a key role in the activation of these genes. The
results of reporter and ChIP assays confirmed this
hypothesis. We found strong inhibition of NF-B-
dependent transcriptional activation and loading of RelA
to the promoters of several genes. Based on these
results, a series of experiments was performed in an
attempt to understand the molecular mechanism under-
lying this activity of TMP.
One hypothesis we considered was a direct inhibitory
effect of TMP on the interaction between RelA and its
cognate sites on the DNA. TMP could be acting on
RelA itself, binding to conserved motifs present in the
amino terminus RHD thereby preventing RelA from
recognizing its DNA binding site. Alternatively, TMP
could be interacting with the DNA, preventing RelA
from occupying its binding sites. In support of this
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Figure 5 TMP does not prevent nuclear translocation of NF-B.
Cells were either left untreated (A) or treated with LPS (1 μg/ml) for
20 (B) or 60 min (C) then stained. In panel D, cells were treated with
25 μM TMP for 60 min while panels D and F show treatments with
LPS and TMP for 20 and 60 min, respectively. Following treatment
cells were fixed, permeabilized and stained with anti-RelA Ab and a
fluorescein coupled secondary Ab. Representative images from a
single experiment are shown in A-F. For G, Photoshop (Adobe) was
used to analyze images and determine mean fluorescence intensity
for the nuclear region of 120 cells at each time point for each
variable (20 cells from two fields from three independent
experiments). Treatment with LPS and LPS in combination with TMP
did not produce significant differences (p < 0.05, T-test).
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Figure 6 TMP fails to affect IB-a phosphorylation. RAW 264.7
cells were stimulated with either 1µg/ml of LPS (A) or 1µg/ml of
LPS and 25µM TMP (B) for the indicated times. Lysates were
prepared and analyzed by western blot with Abs specific for the
phosphorylated serine 32 residue of IB-a and total IB-a.
Representative experiments are shown in panels A and B. For
densitometric analysis (C), phospho-IB-a blots were scanned and
band intensity determined using Photoshop. Values shown are
means +/- SEM from three independent experiments. Treatment
with LPS and LPS in combination with TMP did not produce
significant differences (p < 0.05, T-test).
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Page 8 of 11hypothesis, Chen et al., [13] have shown that TMP can
bind the HSV ICP4 promoter and prevent Sp1 binding.
Additionally, compounds with structures similar to
TMP; 3’-O-methyl NDGA [13,31] and tetra-O-glycyl-
NDGA [32] have been shown to bind DNA and prevent
Sp1 binding. The recent finding that Sp1 can directly
bind to certain NF-B sites on the DNA [33] also sup-
ported this hypothesis and raised the possibility that it is
t h es a m ea c t i v i t yo fT M Pt h a ti sr e s p o n s i b l ef o rb o t h
RelA and Sp1 inhibition of binding. However, the results
of our EMSA experiments did not support this hypoth-
esis. TMP did not interfere with the abilty of RelA to
bind its cognate site when TMP was incubated with
cells prior to nuclear extract preparation. Similarly,
TMP did not inhibit RelA:DNA binding when it was
added in vitro to the nuclear extracts and DNA. We
conclude, therefore, TMP is working indirectly,
upstream of DNA binding in the NF-B pathway to pre-
vent RelA from loading its promoter following LPS
stimulation.
We next considered the hypothesis that TMP inhibits
the signaling pathway that results in RelA translocation
into the nucleus. TLR3/8 transcription was blocked
more effectively than was TLR4. Since both TLR3 and 8
are localized to endosomal compartment this difference
could suggest an effect of TMP on endocytosis. How-
ever, the phosphorylation of IB-a and nuclear translo-
cation of RelA were not altered following treatment
with TMP suggesting that TMP is affecting additional
regulatory systems. The results of our experiments also
showed that, in the presence of TMP, IB-a was
resynthesized normally after treatment with LPS. Tran-
scription of IB-a is dependent on RelA [30] suggesting
that the effect of TMP is selective for only certain RelA:
promoter interactions. Phosphorylation of RelA is a
mechanism that has been shown to confer selectivity for
certain promoters. For example, phosphorylation at
Ser
276 has been shown to be critical for transcription of
IL-8 and GROb/CXCL2 but not IB-a [34]. RelA which
is phosphorylated at this site interacts with positive
transcription elongation factor b (PTEF-b), which is
required for IL-8 and GROb/CXCL2 transcription but
not IB-a [34]. Similarly, phosphorylation at Ser
311 has
been shown to regulate the interaction of RelA with
other transcriptional coactivators such as cyclic AMP-
responsive element binding protein/p300 and RNA poly-
merase II [35-37] while acetylation of RelA is also
known to be a molecular switch that regulates its activ-
ity [38]. Clearly future experiments with TMP will need
to evaluate its effects on the post-translational modifica-
tion of RelA.
The range of inhibitory effects seen with TMP with
different cytokines and chemokines may arise from the
differential requirements of these genes for the various
modified forms of RelA as discussed above. Alterna-
tively, the variation might stem from the degree to
which NF-B RelA is required for transcription of each
gene. For example, several groups have reported that
transcriptional activation of the TNF-a and MCP-1/
CCL2 genes is strongly dependent on the trans-activat-
ing activities of NF-B RelA [17,39], likely explaining
the strong inhibition of these molecules by TMP. Simi-
larly, inhibition of NF-B RelA binding might explain
the strong inhibition of G-CSF production by TMP we
noted previously [14]. NF-B binding sites have been
shown to be present at the G-CSF promoter (CSF box)
[40] and nuclear factors have been shown to associate
with these sequences. In contrast, TMP only weakly
inhibited production of IL-6, MIP-1a/CCL3, and
RANTES/CCL5 [14]. It is possible that for these genes,
although NF-B sites are present in their promoters,
their transcription in RAW 264.7 cells treated with LPS
is not predominantly dependent on NF-B. Transcrip-
tion of IL-6, for example, can be entirely dependent on
NF-IL-6 (C/EBPb) [41]. Similarly, while the MIP-1a/
CCL3 LPS response element does contain an NF-B
c-rel binding site it also contains four C/EBP family
binding sites [42]. For RANTES/CCL5, although Fessele,
et. al. [43] reported that NF-B is essential for LPS-
induced transcription in mono mac 6 cells [43] Shin et.
al. [44] observed that NF-B is not required for its LPS-
induced transcription in RAW 264.7 cells [45] (the cells
we used in our investigation). In agreement, our ChIP
assays showed complete inhibition of RelA binding to
the RANTES/CCL5 promoter, while at the same time
levels of RANTES/CCL5 mRNA and protein were not
blocked by TMP [14].
In addition to the effects we noted on NF-B, in our
experiments we also noted an effect of TMP on the
steady state levels of MCP-1/CCL2 mRNA (Figure 1D).
To our knowledge, post-transcriptional regulation of
MCP-1/CCL2 mRNA has not been reported. It is possi-
ble, that the effects of TMP may be related to the nor-
mal regulation of this mRNA. If levels of TTP-mediated
degradation are normally low, they may be masked by
the high levels of LPS-induced MCP-1/CCL2 transcrip-
tion and only revealed when transcription is effectively
blocked by TMP. In support of this hypothesis, MCP-1/
CCL2 mRNA does contain the TTP AUUUA recogni-
tion site in its 3’ untranslated region. It is also possible
that TMP could be modifying TTP or the 3’ untrans-
lated region to enhance rates of degradation. If so, then
one might also predict enhanced rates of TNF-a mes-
sage degradation, which did not occur.
In summary, we have examined the effects of TMP on
NF-B activation, translocation and binding. We report
that TMP inhibited NF-B- dependent transcription
and NF-B RelA binding at the promoters of TNF-a,
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Page 9 of 11MCP-1/CCL2, and RANTES/CCL5. Since NF-BR e l A -
dependent transcription is critical to numerous inflam-
matory and pathological responses, TMP might be
useful to treat a variety of disorders. The safety of TMP
has been established in several clinical trials, and testing
for efficacy in inflammation should begin immediately.
Conclusions
￿ TMP exerted an early inhibitory effect on the pro-
duction of TNF-a and MCP-1/CCL2 mRNA from
RAW 264.7 cells following treatment with LPS.
￿ TMP also accelerated the loss of MCP-1/CCL2
mRNA from RAW 264.7 cellsf o l l o w i n gt r e a t m e n t
with LPS.
￿ Reporter experiments with HEK293 cells showed
that TMP can inhibit TLR3, TLR4, and TLR-8-
dependent activation of NF-B.
￿ ChIP assays showed that TMP can prevent the NF-
B RelA protein from binding its cognate sites on
the DNA.
￿ Immunofluorescence experiments failed to reveal
an effect of TMP on the nuclear translocation of
RelA.
￿ Western blots failed to reveal an effect of TMP on
the phosphorylation of IB-a.
￿ EMSA assays failed to reveal an effect of TMP on
the direct interaction between RelA and DNA.
￿ TMP should be considered as a candidate drug for
the treatment of inflammation and pathology
mediated by NF-B.
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